Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447439 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL30248352 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL2323271 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL29447428 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL3898874 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL269429 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL269430 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL10062052 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL15092674 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL26719465 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791300-B2 | Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-3210965-B2 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2023209033-A1 | METHOD FOR CRYSTALLIZING TAPENTADOL INTERMEDIATE, TAPENTADOL INTERMEDIATE OF HIGH PURITY, METHOD OF MAKING TAPENTADOL AND TAPENTADOL OF HIGH PURITY | KRKA, D.D., NOVO MESTO (SI) | 2023-11-02 | — | — | WO | disclosed |
| EP-4269384-A1 | METHOD FOR CRYSTALLIZING TAPENTADOL INTERMEDIATE, TAPENTADOL INTERMEDIATE OF HIGH PURITY, METHOD OF MAKING TAPENTADOL AND TAPENTADOL OF HIGH PURITY | KRKA, d.d., Novo mesto (SI) | 2023-11-01 | — | — | EP | disclosed |
| EP-3868739-B1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | Grünenthal GmbH (DE) | 2023-08-29 | — | — | US | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3210965-B1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-20210253513-A1 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL | PHARMATHEN S.A. (GR) | 2021-08-19 | — | — | US | disclosed |
| US-20210130282-A1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2021-05-06 | — | — | US | disclosed |
| WO-2008012046-A1 | PREPARATION OF 3-[(1R,2R)-3-(DIMETHYLAMINO)-1ETHYL-2-METHYLPROPYL]PHENOL | Grünenthal GmbH (DE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012047-A1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012283-A1 | PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012283-A1 | PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-31 | — | — | WO | disclosed |
| US-20060194988-A1 | Process for the preparation of substitued 3-aryl-butylamine compounds | GRUENENTHAL GMBH | 2006-08-31 | — | — | US | disclosed |
| US-20060167318-A1 | Process for the dehydration of substituted 4-dimethylamino-2-aryl-butan-2-ol compounds and process for the preparation of substituted dimethyl-(3-aryl-butyl)- amine compounds by heterogeneous catalysis | GRUENENTHAL GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1636169-A1 | METHOD FOR DEHYDRATING SUBSTITUTED 4-DIMETHYLAMINO-2-ARYL-BUTAN-2-OL COMPOUNDS AND METHOD FOR PRODUCING SUBSTITUTED DIMETHYL-(3-ARYL-BUTYL)-AMINE COMPOUNDS BY MEANS OF HETEROGENEOUS CATALYSIS | Grünenthal GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1633697-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005000788-A1 | METHOD FOR DEHYDRATING SUBSTITUTED 4-DIMETHYLAMINO-2-ARYL-BUTAN-2-OL COMPOUNDS AND METHOD FOR PRODUCING SUBSTITUTED DIMETHYL-(3-ARYL-BUTYL)-AMINE COMPOUNDS BY MEANS OF HETEROGENEOUS CATALYSIS | Grünenthal GmbH (DE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004108658-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167318-A1 | Process for the dehydration of substituted 4-dimethylamino-2-aryl-butan-2-ol compounds and process for the preparation of substituted dimethyl-(3-aryl-butyl)- amine compounds by heterogeneous catalysis | BRD2, BBOX1, BRD1 | SLC22A1 4361/4885OPRM1 1260/4885AOC3 56/4885 |
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | COMT, CYP1A1, CYP2E1 | SLC22A1 4825/4885OPRM1 201/4885AOC3 874/4885 |
| US-20060194988-A1 | Process for the preparation of substitued 3-aryl-butylamine compounds | BRD3, TYR, BBOX1 | SLC22A1 4252/4885OPRM1 131/4885AOC3 46/4885 |
| US-20210130282-A1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | COMT, CYP1A1, CYP2E1 | SLC22A1 4825/4885OPRM1 201/4885AOC3 874/4885 |
| US-20210253513-A1 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL | OPRK1, OPRL1, OPRM1 | SLC22A1 2262/4885OPRM1 3/4885AOC3 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.